Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
07/10/26	US$0.5697	+1.71%	365,535
06/10/26	US$0.5601	-5.52%	328,613
05/10/26	US$0.5928	+4.88%	376,089
02/10/26	US$0.5652	-5.48%	237,389
01/10/26	US$0.5980	+3.10%	294,573

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.5697USD

Average target price

20.00USD

Spread / Average Target

+3,410.62%

Consensus

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Jasper Therapeutics, Inc.

Company calendar

Market Closed - Nasdaq 21:00:00 07/10/2026 BST			5-day change	1st Jan Change
0.5697 ^USD	+1.71%		-1.78%	-68.87%

09-28	Jasper Therapeutics, Inc. Announces CFO Changes, Effective October 9, 2026	CI
09-28	Jasper Therapeutics, Inc. Announces Management Changes, Effective October 9, 2026	CI

Market Cap	18.96M 16.94M 15.8M 14.35M 27.03M 1.83B 27.23M 190M 74.19M 933M 71.17M 69.63M 3B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	18.96M 16.94M 15.8M 14.35M 27.03M 1.83B 27.23M 190M 74.19M 933M 71.17M 69.63M 3B	EV / Sales 2026 *	1.58x	EV / Sales 2027 *	-
Free-Float	97.14%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	JSPR	Delayed
CBOE	JSPR	Real-time

09-28	Jasper Therapeutics, Inc. Announces CFO Changes, Effective October 9, 2026	CI
09-28	Jasper Therapeutics, Inc. Announces Management Changes, Effective October 9, 2026	CI
09-17	Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to NASDAQ Composite Index	CI
09-14	Jasper Therapeutics, Inc. Appoints Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President	CI
08-14	Jasper Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT
08-05	Jasper Therapeutics, Inc. announced that it has received $131.996211 million in funding from a group of investors	CI
07-17	Jasper Therapeutics, Inc. Announces Board, Committee and Executive Changes, Effective July 16, 2026	CI
07-16	Jasper Therapeutics Completes Merger With Kira Pharmaceuticals, Shares Fall	MT
07-15	Kira Pharmaceuticals acquired Jasper Therapeutics, Inc. for approximately $200 million in a reverse merger transaction.	CI
07-15	Jasper Therapeutics, Inc. announced that it expects to receive $131.996211 million in funding	CI
06-02	Jasper Therapeutics Initiates Review of Strategic Alternatives to Maximize Shareholder Value	CI
06-01	Jasper Therapeutics Explores Sale, Merger and Other Strategic Alternatives	MT

Jasper Therapeutics, Inc. Share Price

Stocks

JSPR

US4718712023

Biotechnology & Medical Research

Valuation: Jasper Therapeutics, Inc.

Chart: Jasper Therapeutics, Inc.

Latest news: Jasper Therapeutics, Inc.

Last Transcript: Jasper Therapeutics, Inc.

Analysts' recommendations: Jasper Therapeutics, Inc.

Press Releases: Jasper Therapeutics, Inc.

News in other languages: Jasper Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Jasper Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Net sales - Rate of surprise

08-12	Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target	MT
05-15	RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk	MT
05-15	TD Cowen Downgrades Jasper Therapeutics to Hold From Buy	MT
03-23	UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25	MT
11-11	RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk	MT

10-07	Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants	AQ
09-15	Jasper Therapeutics Announces Key Regulatory and Clinical Appointments	AQ
09-09	Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-17	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
08-14	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ

19/09/25	USA-Les valeurs à suivre à Wall Street (actualisé)
15/11/21	MÄRKTE USA/Kaum verändert - Zwischen China-Hoffnung und Zinssorgen
15/11/21	MÄRKTE USA/Wall Street dreht leicht ins Minus
15/11/21	MÄRKTE USA/Wall Street mit Vorschusslorbeeren für Biden-Xi-Gipfel
15/11/21	MÄRKTE USA/Wall Street vor Biden-Xi-Gipfel leicht optimistisch

1 day	+1.71%
1 week	-1.78%
Current month	-1.78%
1 month	-19.60%
3 months	+18.27%
6 months	-14.69%
Current year	-68.87%

1 week	0.54	0.62
1 month	0.54	0.73
Current year	0.32	2.07
1 year	0.32	2.69
3 years	0.32	31.01
5 years	0.32	188.8
10 years	0.32	188.8

Manager	Title	Age	Since
Jeet Mahal CEO	Chief Executive Officer	54	05/01/2026
Herbert Cross DFI	Director of Finance/CFO	54	21/09/2023
Matthew Ros COO	Chief Operating Officer	59	15/07/2026

Director	Title	Age	Since
Jeet Mahal BRD	Director/Board Member	54	05/01/2026
Judith Shizuru BRD	Director/Board Member	70	03/09/2021
Kurt von Emster BRD	Director/Board Member	59	23/09/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/07/26	Judith Shizuru	Free	Founder	7,500	0.0267%
31/07/26	Patrick Crutcher	Free	Director	7,500	0.0267%
31/07/26	Thomas Wiggans	Free	Chairman	7,500	0.0267%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JASPER THERAPEUTICS, INC.	+1.71%	-1.78%	-76.56%	-92.88%	18.96M
WUXI APPTEC CO., LTD.	+4.16%	+4.16%	+49.37%	+94.17%	74.68B
ARGENX SE	-14.74%	-14.71%	+4.45%	+53.70%	58.7B
LONZA GROUP AG	-1.78%	+0.93%	+3.85%	+31.89%	48.36B
REVOLUTION MEDICINES, INC.	+0.50%	-2.14%	+331.33%	+702.20%	43.05B
IQVIA HOLDINGS INC.	-0.72%	-3.99%	+28.50%	+29.94%	42.48B
BEONE MEDICINES AG	+0.34%	-0.52%	+6.56%	+109.35%	41.39B
CELLTRION, INC.	-0.11%	+1.96%	+9.19%	+52.66%	31.29B
BIONTECH SE	-0.50%	-3.10%	-10.19%	-14.35%	23.93B
INSMED INCORPORATED	-3.32%	-10.86%	-37.32%	+316.28%	22.22B
Average	-1.41%	-2.14%	+30.92%	+128.30%	38.61B
Weighted average by Cap.	-1.83%	-1.56%	+49.45%	+145.26%

	2026 *	2027 *
Net sales	12M 10.72M 10M 9.09M 17.11M 1.16B 17.24M 120M 46.96M 590M 45.05M 44.08M 1.9B	-
Net income	-	-
Net Debt	-	-